Moleculin Biotech - MBRX

"These interim Phase 2/3 results on such a challenging subject population represent a defining moment for Moleculin and, we believe, the strongest clinical validation of Annamycin we have seen to date," said Walter Klemp, Chairman and CEO of Moleculin. Read more on the MIRACLE interim results: https://bit.ly/4bglWkM

Moleculin today announced positive preliminary unblinded efficacy results from the first 45 patients enrolled in Part A of its pivotal Phase 2/3 MIRACLE trial, analyzed on a full intent-to-treat basis with no patient exclusions. Both Annamycin treatment arms outperformed the control arm on the primary endpoint of complete remission (CR): 43% and 36% vs. 12% for control. Read more: https://bit.ly/4bglWkM

Each year, an estimated 20,000 people in the U.S. are diagnosed with Acute Myeloid Leukemia, a fast-moving cancer with significant unmet need.

is focused on advancing therapies to improve outcomes and bring new hope to patients.